ECO Animal Health hen treatment approved in Malaysia
ECO Animal Health Group
66.07p
10:54 15/11/24
ECO Animal Health Group announced on Monday that its subsidiary, ECO Animal Health Limited, had received a marketing authorisation from the National Pharmaceutical Regulatory Agency of Malaysia for the use of Aivlosin 625 mg/g water soluble granules in chickens laying eggs for human consumption.
FTSE AIM 100
3,528.04
15:45 15/11/24
FTSE AIM All-Share
728.67
15:45 15/11/24
Pharmaceuticals & Biotechnology
19,259.77
15:45 15/11/24
The AIM-traded company said the approval - the second in South East Asia - followed the European approval received in June 2016.
ECO said it would start selling Aivlosin in Malaysia for the medication of drinking water for the treatment of infections caused by mycoplasma in poultry laying eggs for human consumption, with a zero day drug withdrawal period for eggs.
The firm said it had also begun the process of submitting the Aivlosin regulatory files for the treatment of layers in numerous other key egg-producing markets.
Aivlosin, which ECO described as its patented antimicrobial, was used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric diseases in poultry and pigs.
“This approval is another important step in the development of Aivlosin for commercial layers,” said chairman Peter Lawrence.
“Malaysia is ranked as a global top twenty egg producing country and home to four of the ten largest egg producers in Asia.
“This latest approval demonstrates ECO’s continued progress to becoming a major force in the international market for veterinary pharmaceutical products.”